NovaScan logo — Easy to use ex vivo and in vivo cancer detection that provid...

NovaScan

Easy to use ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results.

Founded 2003 United States Chicago, United States 16 employees Convertible Note Total: $7.48M Biotechnology, Health Care +1

General Information

Company Name NovaScan
Founded Year 2003
Location United States Chicago, United States
Founders / Decision Makers
Team member
Employees 16
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Convertible Note
Social

BounceWatch is an independent company data service, not affiliated with NovaScan. To contact NovaScan, visit novascaninc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does NovaScan compare?

A PDF of NovaScan and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting NovaScan soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About NovaScan

NovaScan, founded in 2003, is a biotechnology and healthcare company based in the United States. The company's slogan "Easy to use ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results" signifies its novel approach to cancer diagnosis. NovaScan has developed a clinical-stage oncology diagnostic platform for real-time cancer detection and stratification with a low-cost, single-use device. Clinical trials and commercialization efforts are underway for use in lung, breast, skin, GI, and pancreatic cancers, offering the ability to detect malignancy without tissue acquisition. The revolutionary use of the Cole Relaxation Frequency has demonstrated highly accurate results in clinical trials and will provide ex vivo and in vivo detection at the point-of-care, during procedures, and post-procedural pathology. The significant advantages of the platform, including improved patient outcomes, increased physician economies, and reductions in the cost of care, make it an attractive investment opportunity. Notably, NovaScan received a significant $3.00M Convertible Note investment at 22 January 2021 from investors Green Park & Golf Ventures, Stateline Angels, Harvard Business School Angels Chicago, and BioPacific Investors. This latest investment underscores the potential of NovaScan's innovative diagnostic platform.

Business keywords: oncology diagnostic, real-time cancer detection, clinical-stage, Cole Relaxation Frequency, point-of-care testing, cancer stratification, clinical trials, cancer diagnosis, patient outcomes, physician efficiency, cancer research, point-of-care diagnostics, innovative medical technology

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note $3.00M 4
Green Park & Golf Ventures, Stateline Angels +2
22 Jan 2021
Series A Undisclosed 1
Standing Oaks Venture Partners
01 Dec 2019
Venture Round $1.85M -
08 May 2017
Venture Round $250.00K -
24 May 2016
Grant $15.00K 1
Propel
20 Apr 2016
Seed Round Undisclosed 1
Gore Range Capital
20 Apr 2016
Seed Round $75.00K -
01 Jan 2016
Grant $2.29M 1
NSF Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR)
04 Jan 2015
Angel Round Undisclosed -
01 Jan 2012

NovaScan Alternatives & Competitors

View All Alternatives
NovaScan vs
Beacon Biomedical
Beacon Biomedical United States

Easy, Accurate & Affordable Blood Based Screening for early detection of cancer and COVID-19 detecti...

Acquired
1 employees
Biotechnology, Health Care
NovaScan vs

Simplifying lung cancer detection.

Seed
7 employees
Biotechnology, Health Care
NovaScan vs

Leading the world in early cancer detection research.

9 employees
Biotechnology, Health Care

FAQ About NovaScan

Easy to use ex vivo and in vivo cancer detection that provides instantaneous, highly accurate results.
NovaScan was founded in 2003.
NovaScan is headquartered in Chicago, United States.
NovaScan operates in Biotechnology, Health Care and Medical Devices. Its work centres on oncology diagnostic, real-time cancer detection, clinical-stage and Cole Relaxation Frequency.
NovaScan has approximately 16 employees.
NovaScan has completed 9 funding rounds, raising a total of $7.48M. The latest funding stage is Convertible Note.
Top alternatives and competitors to NovaScan include Beacon Biomedical, OncoSwab, Biomark Diagnostics Inc, Optellum, The Royal Marsden NHS Foundation Trust. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
NovaScan and Beacon Biomedical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for NovaScan, https://bouncewatch.com/company/novascan, updated 27 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes